The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study
Open accessAbstract
OBJECTIVE: Diabetes mellitus contributes to excessive cardiovascular deaths and reduced life expectancy in schizophrenia. This population-based cohort study investigated the endogenous risk for diabetes in antipsychotic-naive schizophrenia and evaluated the risks added by starting antipsychotic treatment in people with schizophrenia. METHOD: The study followed all people born in Denmark on or after Jan. 1, 1977, until Jan. 1, 2013 (N=2,736,510). The Danish Psychiatric Central Research Register ascertained schizophrenia diagnoses. The Danish National Prescription Registry provided data on prescriptions of antipsychotics. Diabetes was ascertained from the Danish National Patient Register and Danish National Prescription Registry. The authors estimated the endogenous and antipsychotic-related risks for diabetes by using Cox proportional hazards regression models, while accounting for potential confounders. RESULTS: Of the cohort members, 14,118 (0.52%) developed diabetes, and 8,945 (0.33%) developed schizophrenia during follow-up (49,582,279 person-years). The adjusted hazard ratio for diabetes was 3.07 (95% confidence interval [CI], 1.71-5.41) in antipsychotic-naive schizophrenia compared with the general population. The risk for diabetes after starting antipsychotic treatment was significantly higher (adjusted hazard ratio, 3.64; 95% CI, 1.95-6.82) than the risk in antipsychotic-naive schizophrenia, after adjustment for family history of diabetes and other potential confounders. First-line treatment with either first-generation antipsychotics (adjusted hazard ratio, 3.06; 95% CI, 1.32-7.05) or second-generation antipsychotics (adjusted hazard ratio, 3.44; 95% CI, 1.73-6.83) increased the risk for diabetes without a statistically significant difference. Appropriate sensitivity analyses limited to type 2 diabetes corroborated these results. CONCLUSIONS: Schizophrenia confers a high endogenous risk for diabetes, and the risk is further increased by both first-generation and second-generation antipsychotics. Early detection and effective treatment of diabetes should be an integral part of multidisciplinary management of schizophrenia regardless of antipsychotic drug exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In SCZ, APs add significantly to this risk of metabolic dysregulation, with clozapine and olanzapine carrying the greatest metabolic liability98,99.”
From Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health (2021) · cites this paper as [98]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Danish Civil Registration System
Pedersen, C. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810387965 · Cited by 4,713
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
The Danish National Prescription Registry
Wallach‐Kildemoes, H., Sørensen, H. T., & Hallas, J. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810394717 · Cited by 2,490
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Self-citationThe Danish Psychiatric Central Research Register
Mors, O., Perto, G. P., & Mortensen, P. B. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810395825 · Cited by 1,589
Self-citationTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,352
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 995
Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With Schizophrenia
Ryan, M. C. M., Collins, P. B., & Thakore, J. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.284 · Cited by 828
Research works printed but not linked: 8
- Maudsley H, 1879, The Pathology of Mind
- Baker RA, 2009, Psychopharmacol Bull, 42, 11
- Davis S., 2010, S Afr Pharm J, 77, 22
- WHO, 1967, Manual of the International Classification of Diseases, Eighth Revision (ICD-8)
- WHO, 1992, The ICD-10 Classification of Mental and Behavioural Disorders—Diagnostic Criteria for Research
- Elks ML, 1993, West J Med, 159, 44
- WHO, 2014, Guidelines for ATC Classification and DDD Assignment, 2015
- Uggerby P, 2013, Dan Med J, 60, A4578
Cited by
Sorted by citations
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
MacKenzie, N. E., Kowalchuk, C., Agarwal, S. M., Costa-Dookhan, K. A., Caravaggio, F., Gerretsen, P., Chintoh, A. F., Remington, G. J., Taylor, V. H., Müller, D. J., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00622 · Cited by 209
Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
Grajales, D., Ferreira, V., & Valverde, Á. M. (2019) · Cells · doi:10.3390/cells8111336 · Cited by 194
Dopamine outside the brain: The eye, cardiovascular system and endocrine pancreas
Bucolo, C., Leggio, G. M., Drago, F., & Salomone, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.003 · Cited by 162
Associations Between Non-neurological Autoimmune Disorders and Psychosis: A Meta-analysis
Cullen, A. E., Holmes, S., Pollak, T. A., Blackman, G., Joyce, D. W., Kempton, M. J., Murray, R. M., McGuire, P., & Mondelli, V. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.06.016 · Cited by 157
Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
Stogios, N., Gdanski, A., Gerretsen, P., Chintoh, A. F., Graff-Guerrero, A., Rajji, T. K., Remington, G., Hahn, M. K., & Agarwal, S. M. (2021) · npj Schizophrenia · doi:10.1038/s41537-021-00151-6 · Cited by 98
Metadata
- Authors
- Rajkumar, A. P., Horsdal, H. T., Wimberley, T., Cohen, D., Mors, O., Børglum, A. D., & Gasse, C.
- Affiliations
- King's College London (GB)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2017-07-01
- Volume
- 174
- Issue
- 7
- Pages
- 686-694
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2579288121
- Cited by
- 137
- References
- 53
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 14 · 2023: 13 · 2022: 13 · 2021: 15 · 2020: 12 · 2019: 23 · 2018: 12 · 2017: 10
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Licence
- other-oa
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (acceptedVersion, other-oa)
- Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Aarhus Universitet
- Aarhus Universitetshospital
- National Institute for Health and Care Research (CL-2015-17-008)
- King's College London
- European Commission (279227)
- Lundbeckfonden (R155-2014-1724)
- Sundhedsstyrelsen
- H. Lundbeck A/S
- Menzies Centre for Australian Studies, King's College London, University of London
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- schizophrenia, diabetes mellitus, antipsychotic drugs, typical antipsychotics, atypical antipsychotics, type 2 diabetes, youth, cardiovascular risk
- MeSH terms
- Adult, Denmark, Diabetes Mellitus, Female, Humans, Male, Registries, Risk Factors, Schizophrenia, Antipsychotic Agents, Cohort Studies, Proportional Hazards Models, Early Diagnosis, Young Adult, Early Medical Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
